252 related articles for article (PubMed ID: 27770561)
21. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
[TBL] [Abstract][Full Text] [Related]
22. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
[TBL] [Abstract][Full Text] [Related]
23. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Buti M; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Forns X
Clin Infect Dis; 2016 Jan; 62(1):32-6. PubMed ID: 26371152
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Calvaruso V; Petta S; Ferraro D; La Mantia C; Gibilaro G; Reina G; Di Maio VC; Licata A; Ceccherini-Silberstein F; Di Marco V; Craxì A
Dig Liver Dis; 2022 Aug; 54(8):1117-1121. PubMed ID: 34593348
[TBL] [Abstract][Full Text] [Related]
25. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
[TBL] [Abstract][Full Text] [Related]
26. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
[TBL] [Abstract][Full Text] [Related]
27. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
[TBL] [Abstract][Full Text] [Related]
28. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
Forns X; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Buti M
J Hepatol; 2015 Sep; 63(3):564-72. PubMed ID: 25895428
[TBL] [Abstract][Full Text] [Related]
29. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H; Atsukawa M; Takaguchi K; Senoh T; Michitaka K; Hiraoka A; Fujioka S; Kondo C; Okubo T; Uojima H; Tada T; Yoneyama H; Watanabe T; Asano T; Ishikawa T; Tamai H; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Deguchi A; Itobayashi E; Mikami S; Moriya A; Okubo H; Tani J; Tsubota A; Tanaka Y; Masaki T; Iwakiri K; Kumada T
J Gastroenterol; 2018 Dec; 53(12):1276-1284. PubMed ID: 29740665
[TBL] [Abstract][Full Text] [Related]
30. Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
Lai PC; Chen CH; Jeng LB; Yu TM; Tsai SF; Wu MJ; Cheng SB; Yang SS; Lee TY
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0200321. PubMed ID: 34902265
[TBL] [Abstract][Full Text] [Related]
31. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
Hinrichsen H; Stoehr A; Cornberg M; Klinker H; Heyne R; John C; Simon KG; Guenther V; Martin K; Witte V; Zeuzem S
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):415-423. PubMed ID: 32345848
[TBL] [Abstract][Full Text] [Related]
32. Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Evon DM; Dong M; Reeve BB; Peter J; Michael L; Lok AS; Nelson DR; Stewart PW
J Viral Hepat; 2022 Sep; 29(9):795-806. PubMed ID: 35657133
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Elbasha E; Greaves W; Roth D; Nwankwo C
J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
[TBL] [Abstract][Full Text] [Related]
35. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
[TBL] [Abstract][Full Text] [Related]
36. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
Chen J; Li Y; Li G; Lei P
Ren Fail; 2020 Nov; 42(1):377-380. PubMed ID: 32301365
[TBL] [Abstract][Full Text] [Related]
37. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
[TBL] [Abstract][Full Text] [Related]
39. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
Can J Gastroenterol Hepatol; 2017; 2017():8186275. PubMed ID: 28164081
[No Abstract] [Full Text] [Related]
40. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Zeuzem S; Ghalib R; Reddy KR; Pockros PJ; Ben Ari Z; Zhao Y; Brown DD; Wan S; DiNubile MJ; Nguyen BY; Robertson MN; Wahl J; Barr E; Butterton JR
Ann Intern Med; 2015 Jul; 163(1):1-13. PubMed ID: 25909356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]